JACC Case Rep. 2026 Sep 16;31(37):109454. doi: 10.1016/j.jaccas.2026.109454. Epub 2026 Sep 16.
ABSTRACT
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to decrease heart failure hospitalizations (HFHs) and cardiovascular (CV) death; however, Hispanic/Latino patients and methamphetamine (MA) users have been under-represented.
PROJECT RATIONALE: The purpose of this retrospective study was to assess CV outcomes in the Central Valley region of California within 12 months of starting a SGLT2i.
PROJECT SUMMARY: Overall, 413 patients were included, with non-White patients and MA users accounting for 72% and 27% of the population, respectively. The composite CV outcome occurred in 86 of 413 patients (20.8%), 22% of Whites and 19%-27% of non-Whites. Significantly reduced HFH rates were observed in the overall population and subgroups after 1 year of starting SGLT2i. Reduced left ventricular ejection fraction, prior HFH, and MA use predicted CV outcomes, though the retrospective nature of this analysis limits causal inference.
TAKE-HOME MESSAGE: MA use, prior HFH, and reduced left ventricular ejection fraction predicted CV outcomes, irrespective of ethnicity.
PMID:42752038 | DOI:10.1016/j.jaccas.2026.109454